Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.61 |
| ▸ | IGF1R | P08069 | 4/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.53 |
| ▸ | INSR | P06213 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518039 | 0.94 | EGFR (0.68) | EGFRIGF1RALKINSRKCNH2 | |
| SCHEMBL517407 | 0.89 | EGFR (0.66) | EGFRIGF1RALKINSRKCNH2 | |
| SCHEMBL517404 | 0.88 | EGFR (0.78) | EGFRIGF1RALKINSR | |
| SCHEMBL517477 | 0.84 | EGFR (0.84) | EGFRIGF1RALKINSRMAPK7 | |
| SCHEMBL517589 | 0.82 | EGFR (0.69) | EGFRIGF1RALKINSRKCNH2 | |
| SCHEMBL517948 | 0.81 | EGFR (0.81) | EGFRIGF1RALKINSR | |
| Trifluoroacetic Acid SCHEMBL517839 | 0.81 | ALK (0.73) | EGFRIGF1RALKMAPK7LRRK2 | |
| SCHEMBL517968 | 0.80 | EGFR (0.79) | EGFRIGF1RALKINSR | |
| SCHEMBL517889 | 0.78 | EGFR (0.81) | EGFRIGF1RALKINSRMAPK7 | |
| SCHEMBL517495 | 0.77 | EGFR (0.85) | EGFRIGF1RALKINSRMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | EGFR 40/4885IGF1R 499/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.